乳房手术后使用酮咯酸是否增加血肿风险
该回顾性研究纳入2012年1月至2014年12月接受乳房手术的患者,比较术后使用与未使用酮咯酸者的血肿发生率。总体血肿率为2.8%,使用酮咯酸者血肿率为3.5%,未使用者为2.5%;作者认为在其3年回顾性研究中酮咯酸与血肿形成风险增加无关。
要点
- 总体血肿率为2.8%,使用酮咯酸者3.5%,未使用者2.5%。
- 乳房缩小术者使用酮咯酸血肿率4%,未使用者3.2%。
- 乳房再造术者使用酮咯酸血肿率4%,未使用者3.2%。
核心结论
- 作者认为在其3年回顾性研究中,酮咯酸与血肿形成风险增加无关。
研究设计与样本
- 经机构审查委员会批准后,回顾性审查2012年1月至2014年12月接受乳房手术患者的记录。
- 比较术后使用与未使用酮咯酸患者的术后血肿发生率。
主要发现
- 整个队列总体血肿率为2.8%。
- 使用酮咯酸者血肿率为3.5%,未使用者为2.5%。
- 乳房缩小术患者中,使用酮咯酸者血肿率为4%,未使用者为3.2%。
- 乳房再造术患者中,使用酮咯酸者血肿率为4%,未使用者为3.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ketorolac tromethamine (Toradol), a nonsteroidal antiinflammatory drug, is used with increased frequency given its success in postoperative pain control and the subsequent decreased need for narcotics. Its use has been limited in plastic surgery for fear of postoperative bleeding and hematoma formation. In this study of breast surgery patients, the authors investigated whether ketorolac increased the risk of postoperative hematoma formation. METHODS: After obtaining institutional review board approval, the authors retrospectively reviewed the records of patients undergoing breast surgery from January of 2012 through December of 2014. The authors compared the incidence of postoperative hematomas in patients who did, versus those who did not, receive ketorolac postoperatively. RESULTS: For the entire cohort, the overall hematoma rate was 2.8 percent. Of the patients who received ketorolac, the rate was 3.5 percent; of those who did not, the rate was 2.5 percent. Of the breast reduction patients, the rate was 4 percent in those who received ketorolac versus 3.2 percent in those who did not. Of the breast reconstruction patients, the rate was 4 percent in those who received ketorolac versus 3.2 percent in those who did not. CONCLUSIONS: Recently, the high rates of prescribing postoperative narcotics have received increased attention. Aside from the risk of increased availability of narcotics in the community, the side effects can delay patient recovery. Ketorolac is controversial for postoperative pain control because of the potential risk of bleeding, but in the authors' 3-year retrospective study, it was not associated with an increased risk of hematoma formation. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Nguyen BN, Barta RJ, Stewart CE, et al. Toradol following Breast Surgery: Is There an Increased Risk of Hematoma? Plast Reconstr Surg. 2018. PMID: 29750761. doi:10.1097/PRS.0000000000004361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。